Zero Candida's Frankfurt Stock Exchange Listing: A Game Changer for Women's Health

Zero Candida Technologies, Inc. (TSXV: ZCT) (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, has made a significant stride in its global expansion by successfully listing its shares on the Frankfurt Stock Exchange (FSE) under the trading symbol "9L2". This cross-listing on both the TSX Venture Exchange and the FSE provides increased visibility and access to a broader pool of international investors, particularly in Europe.

Eli Ben Haroosh, Founder & CEO of Zero Candida, expressed his excitement about the listing: "Listing on the Frankfurt Stock Exchange represents a crucial step forward for Zero Candida. The European investment community has been captivated by our innovations from the start, and this listing allows them to directly be a part of our vision and growth journey. With our hospital partnerships and patent applications progressing across Europe, we're thrilled to expand our capital markets presence and accelerate our mission of revolutionizing women's health."

The Frankfurt Stock Exchange (FSE), operated by Deutsche Börse AG, is one of the world's leading trading venues for securities and Germany's largest stock exchange. Recognized for its efficiency and transparency with electronic trading and settlement, the FSE enables smooth cross-border transactions for international investors. This listing provides Zero Candida with a strategic opportunity to connect with international investors and further establish its presence in Europe and beyond.

In addition to the FSE listing, Zero Candida will host an inaugural investor webinar for shareholders and other interested parties on Wednesday, January 22, 2025, at 1:00pm EST (10:00am PST). During the webinar, the ZCT team will offer insights into the progress of their groundbreaking device and technology, provide a corporate update, and outline upcoming milestones for 2025. A question and answer session will follow, allowing participants to ask questions at any time during the live webinar or submit them at the time of registration.

Zero Candida (ZCT) is a publicly traded FemTech company pioneering innovative solutions in women's health. The company is developing an AI-driven, tampon-like device that uses a therapeutic light source with a selected wave-length and intensity to effectively treat the Candida fungus with a demonstrated 99.999% success rate in POC. Vulvo-Vaginal Candidiasis ("VVC") affects about 75% of women globally, with 138 million women affected each year, and 492 million over their lifetime. Recurrent VVC (4 or more episodes per year) is increasingly documented to become drug resistant to existing treatments, since the root cause is poorly understood and addressed. ZCT has successfully completed a safety trial using its pre-clinical device in large animals (sheep), and is finalizing their device for human use in preparation for an upcoming clinical trial, that they secured both funding and agreements with leading hospitals in Israel and Europe for.

With its global patent portfolio applications filed in the United States, Brazil, and Europe, and a final patent granted in South Africa, Zero Candida is addressing unmet needs in women's healthcare and expanding access to underserved populations. By combining hybrid medicine and technology-based diagnostics, ZCT is bringing the field of gynecology into the 21st century. To learn more about Zero Candida, visit www.zero-candida.com.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Forward-Looking Statements
This news release includes certain statements and information that constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, are forward-looking statements. The Company provides no assurance that forward-looking statements and information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information. The Company does not undertake to update any forward-looking statements, other than as required by law.